Efficacy, safety, and predictive biomarkers of neoadjuvant nab-paclitaxel and pembrolizumab in hormone receptor-positive breast cancer: A randomized pilot trial

A Adrienne G. Waks (Department of Medical Oncology, Dana-Farber Cancer Institute) J Jingxin Fu (Department of Chemistry, University of California, One Shields Avenue, Davis, California 95616, United States) X Xiangying Chu B Busem Binboga Kurt T Tianyu Li T Thomas M. Kuntz Y Yizhuo Shen D David Yang K Kevin Meli B Brendan Reardon J Jihye Park (Department of Chemistry) A Ann Partridge D Daniel Abravanel R Rinath Jeselsohn E Eileen Wrabel J Jillian Alberti M Molly DiLullo S Serenity Chen A Ayesha Mohammed-Abreu X Xiaopeng Sun J Justin M. Balko M Miranda Kleijn W William Audeh X Xochitl C. Morgan I Ian E. Krop N Nabihah Tayob E Eliezer M. Van Allen E Elizabeth A. Mittendorf S Sara M. Tolaney (Department of Medical Oncology, Dana-Farber Cancer Institute)